Reach Neuro, Inc.
StreetZero Signal 62
About Reach Neuro, Inc.
Reach Neuro, Inc. was founded in 2021 as a spinout from the University of Pittsburgh and Carnegie Mellon University. The company develops the Avantis device, which pairs approved spinal cord stimulators with nerve-to-muscle mapping to restore arm and hand function in chronic stroke patients with upper limb deficits. It has achieved FDA Breakthrough Device designation, completed a seven-patient feasibility trial, and is conducting a 10-patient pilot study. The technology is being tested in an NIH-funded clinical trial in collaboration with UPMC.
LATEST FUNDINGPrivate Placement
$2.0M
Announced 2026-11-17
TOTAL RAISED$11M
IN THE NEWS
- π Reach Neuro Reaches New HeightsΒ - Neurotech Reports
- π Reach Neuro 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- π Reach Neuro - Products, Competitors, Financials, Employees, Headquarters Locations
- π Reach Neuro, Inc.
- π Reach Neuro - 2026 Funding Rounds & List of Investors - Tracxn
EMPLOYEESβ
FOUNDED2021
HQPittsburgh, PA, United States
Industry
Other Health Care
Tags
NeurotechMedical DevicesStroke RecoveryB2B
Key highlights
- Received FDA Breakthrough Device designation for its spinal cord stimulation technology.
- Founded in 2021 as a University of Pittsburgh and Carnegie Mellon University spinout.
- Completed feasibility trial showing grip strength improvements of 40% and 108% in initial participants.
- Published results in Nature Medicine and is conducting an NIH-funded pilot study at UPMC.
- Raised approximately $11 million total including over $8 million in non-dilutive funding.
Ask StreetZero about Reach Neuro, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account